TransCode Therapeutics Inc Dossier - Source-backed chat

TransCode Therapeutics Inc

RNAZNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.11

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.68Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $28.4M

Enterprise Value $20.1M

Shares Outstanding 16.9M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

TransCode Therapeutics is a clinical-stage biotechnology company pioneering RNA-targeted therapies and immuno-oncology for advanced cancers. While its lead candidate, TTX-MC138, successfully completed its Phase 1a trial with a clean safety profile and durable disease stabilization, the company faces significant near-term liquidity risks. With cash of $12.8 million as of March 31, 2026, the runway is projected to fund operations only through the end of 2026. Strategic acquisitions (Polynoma) and licensing agreements (Unleash Immuno Oncolytics) have expanded the pipeline, but they also increase R&D expenses. A 'Hold' is recommended pending shareholder approval of critical financing proposals at the July 2026 annual meeting and initial efficacy readouts from the newly initiated Phase 2a colorectal cancer trial.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

Stockholders fail to approve critical financing proposals or preferred stock conversions, leading to an inability to access the Yorkville SEPA facility and subsequent Nasdaq delisting. Clinical trial delays or safety signals in the Phase 2a trial further depress investor sentiment, forcing highly dilutive emergency capital raises.

Base CaseCentral scenario

$5.5050%

The company successfully initiates patient enrollment in the Phase 2a trial of TTX-MC138 in collaboration with Quantum Leap Healthcare Collaborative. Stockholders approve key proposals at the July 2026 annual meeting, allowing the company to utilize its flexible financing facilities and maintain Nasdaq compliance, though dilution remains a headwind.

Bull CaseUpside scenario

$10.0030%

The Phase 2a trial of TTX-MC138 in ctDNA-positive colorectal cancer demonstrates robust clinical efficacy and ctDNA clearance, validating the microRNA-10b targeting platform. Shareholder approval of preferred stock conversions and the Yorkville SEPA facility secures a flexible capital runway into late 2027/early 2028, driving a significant valuation re-rating.

Scenarios reflect our research view at the research date.

Key Investment Merits

Successful Phase 1a safety readout for lead candidate TTX-MC138 with no dose-limiting toxicities and durable disease stabilization in metastatic patients.
Initiation of a Phase 2a clinical trial in ctDNA-positive colorectal cancer in collaboration with Quantum Leap Healthcare Collaborative, leveraging the PRE-I-SPY platform.
Expanded pipeline through the acquisition of Polynoma (adding the Seviprotimut-L melanoma vaccine) and licensing of Unleash Immuno Oncolytics' adenovirus platform.

Key Investment Risks

Severe liquidity constraints with cash of $12.8 million only projected to fund operations through the end of 2026.
High dependence on shareholder approval of financing proposals at the July 2026 annual meeting to access capital and maintain Nasdaq compliance.
Substantial historical dilution from multiple reverse stock splits and ongoing equity-heavy dealmaking.

Thesis Invalidation Triggers

Failure of shareholders to approve key proposals at the July 2, 2026 annual meeting.
Emergence of serious adverse safety signals or lack of clinical efficacy (ctDNA clearance) in the Phase 2a colorectal cancer trial.
Delisting from the Nasdaq Capital Market due to failure to regain compliance with listing standards.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.